NeuroSense Therapeutics annual shares outstanding
2021
2022
2023
2024
2025
NeuroSense Therapeutics Shares Outstanding History (NRSN)
NeuroSense Therapeutics reported 32.6M shares outstanding at the end of fiscal 2025.
View full NeuroSense Therapeutics company overviewNeuroSense Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 32.6M | 9.3M | +40.16% |
| 2024 | 2024-12-31 | 23.2M | 23.2M | +645148.36% |
| 2023 | 2023-12-31 | 3,600 | −68,400 | −95.00% |
| 2022 | 2022-12-31 | 72,000 | −1.9M | −96.40% |
| 2021 | 2021-12-31 | 2.0M | — | — |
NeuroSense Therapeutics quarterly shares outstanding
Q4.21
Q4.22
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 32.6M | 32.6M | +904265.94% |
| Q2 2025 | 2025-06-30 | 24.6M | 24.5M | +34070.01% |
| Q4 2024 | 2024-12-31 | 23.2M | 21.2M | +1061.45% |
| Q2 2024 | 2024-06-30 | 18.1M | — | — |
| Q4 2023 | 2023-12-31 | 3,600 | — | — |
| Q4 2022 | 2022-12-31 | 72,000 | — | — |
| Q4 2021 | 2021-12-31 | 2.0M | — | — |
NeuroSense Therapeutics shares outstanding trends
Across the available reported history, NeuroSense Therapeutics's shares outstanding moved from 23.2M to 32.6M, a change of 9.3M. The latest reported quarter, Q4 2025, shows 32.6M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NeuroSense Therapeutics filings at SEC.gov ↗